
Diwaker Daver
Bio: Dr. Davar is a translational oncologist whose research interests lies in translational cancer immunotherapy and early-phase clinical trials. He has been instrumental in the development of first-in-human studies evaluating novel agents targeting TIGIT, GITR, TIM-3, CTLA-3 and other immune checkpoints. Based on emerging data implicating intestinal dysbiosis in mediating non-response to PD-1 blockade, he developed a protocol evaluating fecal microbiota transplant in combination with PD-1 blockade to treat PD-1 non-responders. This first-in-human study was selected for funding by Merck to support the clinical costs. Results demonstrating that microbiome modulation reversed primary resistance to anti-PD-1 and augmented anti-tumor immunity were recently published in Science.

Nikole Kimes, Ph.D.

Peter Marks
Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.

Frederik Madsen
Frederik is co-founder and CEO at Cirqle Biomedical, a women's health company developing OUI®.
OUI is a first-in-class non-hormonal contraceptive that works by topically reinforcing the natural barrier properties of cervical mucus to prevent sperm cells from reaching and fertilising the egg. The novel mechanism of action has been demonstrated to provide breakthrough efficacy in pre-clinical animal studies.
Cirqle has been awarded the Index Award, dubbed the Nobel Prize of the design world, and has been featured by amongst others Forbes, CNN and Wired Magazine for its pioneering work.
Frederik brings unique experience on the opportunities of applying human-centred innovation in women's health. He holds a MSc in Management of Innovation and Business Development from Copenhagen Business School.

Emily Zhen

Elena Gambon

Dr. Patrick Carroll

Deena Shakir
Akash Bashi
